Meningeal-derived stem cells

The current patent covers a type of multipotent stem cell derived from the meninges.  This is the three layered membrane that surrounds the cerebrospinal fluid and central nervous system.  The inventors have demonstrated that cells isolated from this membrane, regardless of whether they are from the dura mater, pia mater, or arachnoid mater, can be substantially expanded in vitro...

Dedifferentiated, programmable stem cells of monocytic origin, and their production and use

This patent is highly interesting in that the inventors claim to have devised a simple and easy to implement methodology for generation of autologous stem cells. Essentially, the invention teaches that culturing of peripheral blood monocytes in the presence of IL-3 and M-CSF for approximately 6 days, somehow induces a program of de-differentiation in the monocytes to endow them with stem...

Date of First Priority Issue: Thursday March 28th, 2002 8 Comments

Dedifferentiated, programmable stem cells of monocytic origin, and their production and use

This patent is related to #7,138,275, which covers the composition of matter of a "A dedifferentiated, programmable cell of human monocytic origin, wherein said dedifferentiated, programmable cell of human monocytic origin expresses a CD14 antigen, a CD90 antigen, and a CD123 antigen."

The current patent covers the process of attaining...

Date of First Priority Issue: Thursday March 28th, 2002 1 Comment

STAT3 activated stem cell

One of the major problems in stem cell research is how to maintain the stem cell in an undifferentiated state while allowing for it to continue proliferating.  In the area of embryonic stem cells this was solved by the discovery that leukemia inhibitory factor (LIF) would maintain mouse embryonic stem cells in an undifferentiated state.  For human...

Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells

Stem cell populations are known from the cord blood as well as the placental matrix. In the current patent a stem cell population from the placenta is covered that possesses markers of adult stem cells as well as embryonic stem cells. For example, the first claim...

Date of First Priority Issue: Wednesday February 13th, 2002 2 Comments

Methods for cloning non-human mammals using reprogrammed donor chromatin or donor cells

This patent covers the use of epigenetically reprogramming a donor nucleus prior to cloning. Essentially Collas uses methods he previously described as able to induce dedifferentiation of adult cells. In previous papers, Collas demonstrated that tranfering cytoplasm from a T cell into a fibroblast (through temporarily permeabilizing the fibroblast), will allow the fibroblast to express T cell...

Placental stem cells

This patent covers stem cells obtained from the placenta, in some ways similar to Hariri's other patents in this area such as #7,255,879 Post-partum mammalian placenta, its use and placental stem cells therefrom and #7,311,905 Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment...

Immortalized bone marrow mesenchymal stem cell

This patent has one claim that covers a specific mesenchymal stem cell population that is immortalized and appears to contain a gene associated with immortalization.

Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos

This patent teaches methods of generating a composite blastocyst from non-viable embryos. The invention is useful for generation of stem cells of embryonic origin through a novel method.